Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria

키워드

참고문헌 (90)

1. Bongyoung Kim, "Ten-year trends in antibiotic usage at a tertiary care hospital in Korea, 2004 to 2013", The Korean Journal of Internal Medicine, 35(3), pp.703~713 (2020), 대한내과학회[DOI]
2. Wilfredo Flores-Paredes, "Evolution of Antimicrobial Resistance Levels of ESKAPE Microorganisms in a Peruvian IV-Level Hospital", Infection and Chemotherapy, 53(3), pp.449~462 (2021), 대한감염학회[DOI]
3. Piyatip Khuntayaporn, "Dissemination of Carbapenem-Resistance among Multidrug Resistant Pseudomonas aeruginosa carrying Metallo-Beta-Lactamase Genes, including the Novel blaIMP-65 Gene in Thailand", Infection and Chemotherapy, 51(2), pp.107~118 (2019), 대한감염학회[DOI]
4. Butler MS, "Antibiotics in the clinical pipeline in October 2019", J Antibiot (Tokyo), 73, pp.329~364 (2019)
5. Duval RE, "Fight against antimicrobial resistance : we always need new antibacterials but for right bacteria", Molecules, 24, pp.3152~ (2019)
6. 이창섭, "Are Community-Based Hospitals Safe from Carbapenem-Resistant Enterobacteriaceae in Korea?", Infection and Chemotherapy, 48(3), pp.246~248 (2016), 대한감염학회
7. 김현순, "Factors Associated with Vancomycin-Resistant Enterococcus Colonization in Patients Transferred to Emergency Departments in Korea", Journal of Korean Medical Science, 33(48), pp.1~7 (2018), 대한의학회
8. Choi Young Kyun, "Antibiotic Resistance Patterns of Enterobacteriaceae Isolated from Patients with Healthcare-Associated Infections", Infection and Chemotherapy, 53(2), pp.355~363 (2021), 대한감염학회[DOI]
9. Jeongmin Hong, "Management of carbapenem-resistant Acinetobacter baumannii epidemic in an intensive care unit using multifaceted intervention strategy", The Korean Journal of Internal Medicine, 33(5), pp.1000~1007 (2018), 대한내과학회[DOI]
10. Sung Min Jung, "Cancer patients with neutropenic septic shock: etiology and antimicrobial resistance", The Korean Journal of Internal Medicine, 35(4), pp.979~987 (2020), 대한내과학회[DOI]
11. Sobhanipoor Mohammad Hossein, "Reduced Susceptibility to Biocides among Enterococci from Clinical and Non-Clinical Sources", Infection and Chemotherapy, 53(4), pp.696~704 (2021), 대한감염학회[DOI]
12. Young Ah Kim, "Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea", The Korean Journal of Internal Medicine, 33(2), pp.247~255 (2018), 대한내과학회[DOI]
13. Liu C, "Antimicrobial resistance in South Korea : a report from the Korean global antimicrobial resistance surveillance system(Kor-GLASS)for 2017", J Infect Chemother, 25, pp.845~859 (2019)
14. 박정완, "The Rate of Acquisition of Carbapenemase-Producing Enterobacteriaceae among Close Contact Patients Depending on Carbapenemase Enzymes", Infection and Chemotherapy, 52(1), pp.39~47 (2020), 대한감염학회[DOI]
15. "2020 Drug approval report" (2021)[URL]
16. Saravolatz LD, "Oritavancin : a long-half-life lipoglycopeptide", Clin Infect Dis, 61, pp.627~632 (2015)
17. Saravolatz LD, "Telavancin : a novel lipoglycopeptide", Clin Infect Dis, 49, pp.1908~1914 (2009)
18. Das B, "Telavancin : a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens", Ther Adv Infect Dis, 4, pp.49~73 (2017)
19. Stryjewski ME, "Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria", Clin Infect Dis, 40, pp.1601~1607 (2005)
20. 추은주, "메티실린 내성 황색포도알균 감염의 항생제 치료", 대한의사협회지, 61(3), pp.207~213 (2018), 대한의사협회[DOI]
21. Sandrock CE, "The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia", Clin Infect Dis, 61(Suppl 2), pp.S79~S86 (2015)
22. Corey GR, "Single-dose oritavancin in the treatment of acute bacterial skin infections", N Engl J Med, 370, pp.2180~2190 (2014)
23. Dunne MW, "A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection", Clin Infect Dis, 62, pp.545~551 (2016)
24. Boucher HW, "Once-weekly dalbavancin versus daily conventional therapy for skin infection", N Engl J Med, 370, pp.2169~2179 (2014)
25. Gonzalez D, "Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age", Pediatr Infect Dis J, 36, pp.645~653 (2017)
26. Soriano A, "The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections(ABSSSIs)", Expert Rev Anti Infect Ther, 18, pp.415~422 (2020)
27. Saravolatz LD, "Ceftaroline : a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus", Clin Infect Dis, 52, pp.1156~1163 (2011)
28. Scott LJ, "Ceftaroline fosamil : a review in complicated skin and soft tissue infections and community-acquired pneumonia", Drugs, 76, pp.1659~1674 (2016)
29. Corey GR, "Integrated analysis of CANVAS 1 and 2 : phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection", Clin Infect Dis, 51, pp.641~650 (2010)
30. Corey GR, "CANVAS 1: the first phase III, randomized, double-blind study evaluating Ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections", J Antimicrob Chemother, 65(Suppl 4), pp.iv41~iv51 (2010)
31. Corrado ML, "Integrated safety summary of CANVAS 1 and 2trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections", J Antimicrob Chemother, 65(Suppl 4), pp.iv67~iv71 (2010)
32. Wilcox MH, "CANVAS 2: the second phase III, randomized, double-blind study evaluating Ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections", J Antimicrob Chemother, 65(Suppl 4), pp.iv53~iv65 (2010)
33. File TM Jr, "Integrated analysis of FOCUS 1 and FOCUS 2 : randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of Ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia", Clin Infect Dis, 51, pp.1395~1405 (2010)
34. Zhanel GG, "Lefamulin : a novel oral and intravenous pleuromutilin for the treatment of community-acquired bacterial pneumonia", Drugs, 81, pp.233~256 (2021)
35. Watkins RR, "Lefamulin : a novel semisynthetic pleuromutilin antibiotic for community-acquired bacterial pneumonia", Clin Infect Dis, 71, pp.2757~2762 (2020)
36. Paukner S, "Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia : SENTRY antimicrobial surveillance program(2015-2016)", Antimicrob Agents Chemother, 63, pp.e02161-18~ (2019)
37. File TM, "Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia : the phase III lefamulin evaluation against pneumonia(LEAP 1)trial", Clin Infect Dis, 69, pp.1856~1867 (2019)
38. Alexander E, "Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia : the LEAP 2 randomized clinical trial", JAMA, 322, pp.1661~1671 (2019)
39. Rubino CM, "Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections", Antimicrob Agents Chemother, 59, pp.282~288 (2015)
40. Scott LJ, "Delafloxacin : a review in acute bacterial skin and skin structure infections", Drugs, 80, pp.1247~1258 (2020)
41. Siala W, "Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates", Antimicrob Agents Chemother, 58, pp.6385~6397 (2014)
42. Saravolatz LD, "Delafloxacin : a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone", Clin Infect Dis, 68, pp.1058~1062 (2019)
43. Saravolatz LD, "Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid", J Antimicrob Chemother, 75, pp.2605~2608 (2020)
44. Pfaller MA, "In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014", Antimicrob Agents Chemother, 61, pp.e02609-16~ (2017)
45. O’Riordan W, "A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections : a phase 3, multinational, double-blind, randomized study", Clin Infect Dis, 67, pp.657~666 (2018)
46. Pullman J, "Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections : a phase 3, double-blind, randomized study", J Antimicrob Chemother, 72, pp.3471~3480 (2017)
47. O’Riordan W, "A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections", Int J Infect Dis, 30, pp.67~73 (2015)
48. Horcajada JP, "A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia(DEFINE-CABP)", Open Forum Infect Dis, 7, pp.ofz514~ (2019)
49. Iregui A, "Emergence of delafloxacin-resistant Staphylococcus aureus in Brooklyn, New York", Clin Infect Dis, 70, pp.1758~1760 (2020)
50. Wu JY, "Cefiderocol : a novel agent for the management of multidrug-resistant Gram-negative organisms", Infect Dis Ther, 9, pp.17~40 (2020)
51. Syed YY, "Cefiderocol : a review in serious Gram-negative bacterial infections", Drugs, 81, pp.1559~1571 (2021)
52. Tamma PD, "Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections", Clin Infect Dis (2021)[DOI]
53. Iregui A, "Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City", Microb Drug Resist, 26, pp.722~726 (2020)
54. Yamano Y, "In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria", Clin Infect Dis, 69(Suppl 7), pp.S544~S551 (2019)
55. Kazmierczak KM, "In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase-and metallo-β-lactamase-producing isolates(SIDERO-WT-2014Study)", Int J Antimicrob Agents, 53, pp.177~184 (2019)
56. Karlowsky JA, "In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016 : SIDERO-WT-2015", Int J Antimicrob Agents, 53, pp.456~466 (2019)
57. Portsmouth S, "Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens : a phase 2, randomised, double-blind, non-inferiority trial", Lancet Infect Dis, 18, pp.1319~1328 (2018)
58. Wunderink RG, "Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia(APEKSNP) : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Infect Dis, 21, pp.213~225 (2021)
59. Bassetti M, "Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria(CREDIBLE-CR) : a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial", Lancet Infect Dis, 21, pp.226~240 (2021)
60. Streling AP, "Evolution of cefiderocol non-susceptibility in pseudomonas aeruginosa in a patient without previous exposure to the antibiotic", Clin Infect Dis, 73, pp.e4472~e4474 (2021)
61. Hobson CA, "Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect", Clin Microbiol Infect, 27, pp.1172~ (2021)[DOI]
62. 이효진, "카바페넴 내성 장내세균: 최신지견과 치료전략", 대한의사협회지, 61(4), pp.281~289 (2018), 대한의사협회[DOI]
63. Shirley M, "Ceftazidime-avibactam : a review in the treatment of serious Gram-negative bacterial infections", Drugs, 78, pp.675~692 (2018)
64. Mazuski JE, "Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection : results from a randomized, controlled, double-blind, phase 3program", Clin Infect Dis, 62, pp.1380~1389 (2016)
65. Wagenlehner FM, "Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis : RECAPTURE, a phase 3 randomized trial program", Clin Infect Dis, 63, pp.754~762 (2016)
66. van Duin D, "Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae", Clin Infect Dis, 66, pp.163~171 (2018)
67. Torres A, "Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia(REPROVE) : a randomised, double-blind, phase 3 non-inferiority trial", Lancet Infect Dis, 18, pp.285~295 (2018)
68. Pogue JM, "Ceftazidime", avibactam, meropenem, Clin Infect Dis, pp.2019, 68[DOI]
69. Tamma PD, "Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales(ESBL-E), carbapenem-resistant Enterobacterales(CRE), and pseudomonas aeruginosa with difficult-to-treat resistance(DTR-P. aeruginosa)", Clin Infect Dis, 72, pp.1109~1116 (2021)
70. Zhang P, "Emergence of ceftazidime", avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China, 2020, pp.26, 124~
71. Shields RK, "Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3mutations during treatment of carbapenem-resistant klebsiella pneumoniae infections", Antimicrob Agents Chemother, 61, pp.e02097~16 (2017)
72. Gottig S, "Emergence of ceftazidime", avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo, 2019, pp.74, 3211~3216
73. Dietl B, "Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales", Future Microbiol, 15, pp.473~484 (2020)
74. Heo YA, "Imipenem", cilastatin, Drugs, pp.2021, 81[DOI]
75. Titov I, "A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem", cilastatin, tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia(RESTORE-IMI 2 Study), pp.Clin Infect Dis, 2021[DOI]
76. Syeda Sahra, "Clinical and Microbiologic Efficacy and Safety of Imipenem", Cilastatin, Infection and Chemotherapy, pp.2021, 53(2)[DOI]
77. Sims M, "Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem", cilastatin plus relebactam with imipenem, J Antimicrob Chemother, pp.2017, 72[DOI]
78. Kaye KS, "Comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 phase 3 trial of imipenem-cilastatin-relebactam versus colistin plus imipenem-cilastatin in patients with imipenem-nonsusceptible bacterial infections", Antimicrob Agents Chemother, 64, pp.e02203~19 (2020)
79. Novelli A, "Meropenem", vaborbactam : a next generation β-lactam β-lactamase inhibitor combination, 2020, pp.18, 643~655
80. Kaye KS, "Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection : the TANGO I randomized clinical trial", JAMA, 319, pp.788~799 (2018)
81. Wunderink RG, "Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections : the TANGO II randomized clinical trial", Infect Dis Ther, 7, pp.439~455 (2018)
82. Zhanel GG, "Review of eravacycline, a novel fluorocycline antibacterial agent", Drugs, 76, pp.567~588 (2016)
83. Solomkin JS, "IGNITE4 : results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections", Clin Infect Dis, 69, pp.921~929 (2019)
84. Tang HJ, "The safety of eravacycline in the treatment of acute bacterial infection", Clin Infect Dis, 70, pp.2750~2751 (2020)
85. Ding Y, "Emergence of tigecyclineand eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans", J Antimicrob Chemother, 75, pp.3480~3484 (2020)
86. Miri Hyun, "Changing trends in clinical characteristics and antibiotic susceptibility of Klebsiella pneumoniae bacteremia", The Korean Journal of Internal Medicine, 33(3), pp.595~603 (2018), 대한내과학회[DOI]
87. Jungok Kim, "Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis", The Korean Journal of Internal Medicine, 35(1), pp.215~221 (2020), 대한내과학회[DOI]
88. 목정하, "Clinical efficacy of matrix-assisted laser desorption", ionization time-of-flight mass spectrometry in patients with multidrug-resistant bacteremia: a single-center study in Korea, 2019, pp.34(5), 1058~1067[DOI]
89. Yoon Young Kyung, "Guidelines on Implementing Antimicrobial Stewardship Programs in Korea", Infection and Chemotherapy, 53(3), pp.617~659 (2021), 대한감염학회[DOI]
90. Hwang Soyoon, "Core Elements for Successful Implementation of Antimicrobial Stewardship Programs", Infection and Chemotherapy, 53(3), pp.421~435 (2021), 대한감염학회[DOI]

관련 논문AI추천